Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3270 - TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)


09 Oct 2016


Poster display


Toni Choueiri


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


T.K. Choueiri1, N. Agarwal2, T. Ho3, S.K. Pal4, B. Seon5, M. Jivani6, B. Adams6, R. Shazer6, C. Theuer6

Author affiliations

  • 1 Kidney Cancer Center, Dana-Farber Cancer Institute, MA 02215 - Boston/US
  • 2 Medical Oncology, Huntsman Cancer Institute, Salt Lake City/US
  • 3 Division Of Hematology/oncology, Mayo Clinic Cancer Center, Scottsdale/US
  • 4 Medical Oncology And Experimental Therapuetics, City of Hope, 91010 - Duarte/US
  • 5 Department Of Immunology, Roswell Park Cancer Institute, Buffalo/US
  • 6 Clinical Operations, TRACON Pharmaceuticals, Inc., San Diego/US


Abstract 3270


Resistance to VEGF-targeted therapy is a major challenge in the contemporary treatment of mRCC, and endoglin activation may be an important mechanism leading to resistance. Endoglin is an essential angiogenic receptor expressed on proliferating tumor vessels and RCC stem cells, and is upregulated following VEGF inhibition. TRC105 is an endoglin monoclonal antibody that potentiates the anti-tumor activity of bevacizumab and VEGF receptor tyrosine kinase inhibitors in preclinical models. 18 patients were enrolled in phase 1b trial and, TRC105 dose escalation proceeded from 8 mg/kg (n = 3) to 10 mg/kg (n = 15) without dose limiting toxicity. TRC105 at its RP2D of 10 mg/kg was well tolerated with axitinib (A) 5 mg BID in RCC patients. Dose escalation of A to 10 mg BID was possible with the RP2D of TRC105. In phase 1b, the combination of TRC105 and A demonstrated preliminary evidence of activity, including partial responses in 29% of patients by RECIST 1.1, and longer PFS than expected with A as a single agent. The overall disease control rate (CR/PR/SD > 2 months) was 88% (15 of 17). Median PFS overall was 8.4 months, and was 9.6 months among patients with clear cell RCC. Adverse events characteristic of each drug were not increased in frequency or severity when the two drugs were administered concurrently, and most commonly included epistaxis, diarrhea, fatigue, headache, and gingival bleeding.

Trial design

Phase 2 is a multicenter study that is actively enrolling at this time across approximately 30 sites in the US. In phase 2, 150 patients are randomized 1:1 to A +/- TRC105. Key inclusion criteria: 1 prior VEGF inhibitor, clear cell RCC, ECOG ≤ 1; one prior mTOR and one prior immune therapy are allowed. Primary endpoint is PFS and secondary endpoints are ORR, disease control rate, and to characterize the pharmacokinetic profile of TRC105 and A. (NCT01806064).

Clinical trial identification

Protocol # 105RC101 (NCT01806064)

Legal entity responsible for the study

TRACON Pharmacuticals, Inc. Lead PI: Toni Choueiri


TRACON Pharmacuticals, Inc.


T. Choueiri: Consulting or Advisory Role: Pfizer, Novartis, GSK, Merck, BMS, Roche, Eisai, Prometheus Labs, Inc., Foundation Medicine Inc. Cerulean Research Funding (Institution): Pfizer, Novartis, Merck, Exelixis, TRACON, GSK, BMS, AstraZeneca, Peloton, Roche. N. Agarwal: Consultancy to Pfizer, Exelixis, Argos, Cerulean, and Medivation. S.K. Pal: consulting for Pfizer. B. Seon: patents - roswell park cancer institute. M. Jivani, B. Adams, C. Theuer: Employee of TRACON Pharmaceuticals, Inc. Stock ownership in TRACON Pharmaceuticals, Inc. R. Shazer: Employee of TRACON Pharmaceuticals, Inc. Stock ownership in BMS All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings